Tumour testing and germline testing can involve some of the same genes while answering different questions. Tumour testing examines genetic changes in a cancer, often to help characterize it or identify treatment options. Germline testing evaluates a person’s constitutional genetic information to assess inherited susceptibility. Confusing these purposes can lead to inappropriate reassurance or unnecessary concern for relatives.
Identify the sample and the intended use
The National Cancer Institute’s genetic-testing fact sheet distinguishes testing for inherited cancer susceptibility from testing genetic changes in tumour cells. It also explains that results require interpretation alongside personal and family history. The first step in reviewing a result is therefore to obtain the actual report, including sample type, genes assessed, method and interpretation. Read the NCI genetic-testing fact sheet.
A variant found in tumour material may be acquired in the tumour or present constitutionally. The tumour result alone may not resolve that distinction. Conversely, a tumour test’s failure to report a variant does not necessarily exclude an inherited predisposition, because its purpose, coverage and reporting thresholds may differ from a germline assay.
Recognize the overlap without assuming it
BRCA1 and BRCA2 provide a familiar example. NCI describes how a harmful change discovered during tumour testing can raise the question of an inherited variant. The finding may have implications beyond the current cancer, but that possibility needs appropriate evaluation. It should not be communicated to a family as an established inherited result before its constitutional significance is clarified. Read the NCI BRCA fact sheet.
A useful handoff separates the treatment question from the hereditary-risk question. Document what the tumour report establishes, what it only suggests, and which team will evaluate any unresolved inherited-risk concern. Different classifications may also be used for tumour relevance and germline pathogenicity; identical wording should not be assumed to mean identical evidence.
Communicate the remaining uncertainty
- Clarify whether matched normal material was analyzed and for what purpose.
- Review whether the report recommends follow-up germline assessment.
- Keep personal and family history relevant even when a tumour report is negative.
The goal is a coordinated interpretation across oncology, pathology and genetics. A shared gene name creates a connection between tests, but the clinical meaning comes from the specimen, the analytic scope and the evidence supporting the result.